TCG Crossover GP I, LLC - Significant Ownership

Signature - Title
/s/ Craig Skaling - Authorized Signatory
Location
Palo Alto, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by TCG Crossover GP I, LLC.

Significant Ownership of TCG Crossover GP I, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ABVX Abivax SA Ordinary Shares, par value Euro 0.01 per share 9.1% $604M 7.11M Chen Yu Sep 30, 2025
TYRA Tyra Biosciences, Inc. Common Stock, par value $0.0001 per share 5.7% $23.1M 2.9M TCG Crossover GP I, LLC Feb 27, 2025
TRDA Entrada Therapeutics, Inc. Common Stock, par value $0.0001 per share 5% $11.8M 1.92M TCG Crossover GP I, LLC Nov 19, 2025
COGT Cogent Biosciences, Inc. Common Stock, par value $0.001 per share 4.8% $97.6M 6.8M TCG Crossover GP I, LLC Sep 30, 2025
CGON CG Oncology, Inc. Common Stock, par value $0.0001 per share 4.8% $57.2M 3.67M TCG Crossover GP I, LLC Mar 31, 2025
UPB Upstream Bio, Inc. Common Stock, par value $0.001 per share 3.9% $39.8M -$12.9M 2.12M -24.4% TCG Crossover GP I, LLC Sep 30, 2025
CMPS COMPASS Pathways plc Ordinary Shares, nominal value 0.008 per share 3.9% $18.6M 3.86M Chen Yu Jun 30, 2025
Jade Biosciences, Inc. Common Stock, $0.0001 par value per share 0.2% 64K TCG Crossover GP I, LLC Apr 28, 2025
ANTX AN2 Therapeutics, Inc. Common Stock, $0.00001 par value 0% $0 0 TCG Crossover GP I, LLC Dec 31, 2024

Schedules 13D/G Reported by TCG Crossover GP I, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.